Gain Therapeutics (GANX) vs NeOnc Technologies (NTHI)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Gain Therapeutics (GANX) has outperformed NeOnc Technologies (NTHI) over the past year, losing 22.0% versus a loss of 76.8%. NeOnc Technologies is the larger company by market cap ($80.1 million vs $71.6 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | GANX | NTHI |
|---|---|---|
| Share price | $1.64 | $2.78 |
| Market cap | $71.58M | $80.08M |
| 1-day change | +1.55% | +9.88% |
| YTD return | -49.84% | -66.38% |
| 1-year return | -21.98% | -76.79% |
| 5-year return | -76.73% | — |
| EPS (TTM) | $-0.51 | $-2.34 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $4.34 | $12.09 |
| 52-week low | $1.53 | $2.50 |
| Distance from 52-week high | -62.21% | -77.01% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +339.02% | +511.51% |
| Average volume | 492.13K | 195.17K |
| Shares outstanding | 43.64M | 28.81M |
| Employees | 20 | 5 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- GANX has outperformed NTHI by 54.8 percentage points over the past year.
About Gain Therapeutics
GANX stock →Gain Therapeutics, Inc., a biotechnology company, develops novel small molecule therapeutics to treat diseases across various therapeutic areas in Switzerland, Spain, the United States, and Australia. The company's drug discovery platform Magellan discovers novel allosteric binding sites in a disease; identifies proprietary small molecules that bind these sites to modulate protein function; and treats the underlying cause of the disease.
Health Care · Biotechnology: Pharmaceutical Preparations · 20 employees
About NeOnc Technologies
NTHI stock →NeOnc Technologies Holdings, Inc., a clinical-stage biopharmaceutical company, focuses on developing treatments for intracranial malignancies. Its lead product candidates include NEO100, a purified form of preillyl acid that is in Phase IIa clinical trial; and NEO212, a covalently conjugated molecule combining chemotherapeutic drug temozolomide with perillyl alcohol that is in Phase I/II clinical trials for its oral administration for the treatment of primary brain cancers, such as meningioma, high grade gliomas, glioblastoma, and secondary brain cancers.
Health Care · Biotechnology: Pharmaceutical Preparations · 5 employees
GANX vs NTHI FAQ
Which is bigger, Gain Therapeutics or NeOnc Technologies?
NeOnc Technologies (NTHI) is larger, with a market capitalization of $80.08M compared with $71.58M for Gain Therapeutics (GANX).
Which stock has performed better over the past year, GANX or NTHI?
GANX returned -21.98% over the past 12 months, compared with -76.79% for NTHI (price return, excluding dividends). Past performance does not predict future results.
Are Gain Therapeutics and NeOnc Technologies in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.